Paclitaxel inhibits osteoclast formation and bone resorption via influencing mitotic cell cycle arrest and RANKL-induced activation of NF-kB and ERK

Journal of Cellular Biochemistry

Volumn 113, Issue 3, 2012, Pages 946-955

  Ang, Estabelle S M ^a   Pavlos, Nathan J ^a   Chim, Shek Man ^a   Feng, Hao Tian ^a   Scaife, Robin M ^b   Steer, James H ^c   Zheng, Ming H ^a   Xu, Jiake ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Bone Resorption; Nf Kb; Osteoclastogenesis; Paclitaxel; Rankl

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; PACLITAXEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE ARREST; CELL FUNCTION; CHEMICAL ANALYSIS; CONTROLLED STUDY; CYTOSKELETON; DRUG ACTIVITY; GIANT CELL TUMOR; HUMAN; HUMAN CELL; MITOSIS; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BONE NEOPLASMS; BONE RESORPTION; CELL LINE; CYTOSKELETON; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GIANT CELL TUMOR OF BONE; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MICE; MICE, INBRED C57BL; MITOSIS; NF-KAPPA B; OSTEOCLASTS; OSTEOLYSIS; PACLITAXEL; RANK LIGAND;

EID: 84863268627     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23423     Document Type: Article

References (33)

1. Abal M, Andreu JM, Barasoain I. 2003. Taxanes: Microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 3:193-203. (Pubitemid 36565761)
2. Ang E, Liu Q, Qi M, Liu HG, Yang X, Chen H, Zheng MH, Xu J. 2011a. Mangiferin attenuates osteoclastogenesis, bone resorption, and RANKLinduced activation of NF-kappaB and ERK. J Cell Biochem 112:89-97.
3. Ang ES, Yang X, Chen H, Liu Q, Zheng MH, Xu J. 2011b. Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF-kappaB and ERK activation. FEBS Lett 585:2755-2762.
4. Ang ES, Zhang P, Steer JH, Tan JW, Yip K, Zheng MH, Joyce DA, Xu J. 2007. Calcium/calmodulin-dependent kinase activity is required for efficient induction of osteoclast differentiation and bone resorption by receptor activator of nuclear factor kappa B ligand (RANKL). J Cell Physiol 212: 787-795. (Pubitemid 47267548)
5. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R. 2001. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 20:147-155. (Pubitemid 32150260)
6. Bhalla KN. 2003. Microtubule-targeted anticancer agents and apoptosis. Oncogene 22:9075-9086. (Pubitemid 38121708)
7. Dziadyk JM, Sui M, Zhu X, Fan W. 2004. Paclitaxel-induced apoptosis may occur without a prior G2/M-phase arrest. Anticancer Res 24:27-36. (Pubitemid 38279685)
8. Hall TJ, Jeker H, Schaueblin M. 1995. Taxol inhibits osteoclastic bone resorption. Calcif Tissue Int 57:463-465.
9. Harvey HA. 1997. Issues concerning the role of chemotherapy and hormonal therapy of bone metastases from breast carcinoma. Cancer 80:1646-1651. (Pubitemid 27444036)
10. Hotokezaka H, Sakai E, Kanaoka K, Saito K, Matsuo K, Kitaura H, Yoshida N, Nakayama K. 2002. U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7cells into osteoclast-like cells. J Biol Chem 277:47366-47372. (Pubitemid 36159251)
11. Huang L, Xu J, Wood DJ, Zheng MH. 2000. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: Possible involvement in tumor cell-induced osteoclastlike cell formation. Am J Pathol 156:761-767. (Pubitemid 30626932)
12. Hwang S, Ding A. 1995. Activation of NF-kappa B in murine macrophages by taxol. Cancer Biochem Biophys 14:265-272.
13. Jordan MA, Wilson L. 2004. Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253-265. (Pubitemid 38525281)
14. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176. (Pubitemid 28180851)
15. Li L, Khansari A, Shapira L, Graves DT, Amar S. 2002. Contribution of interleukin-11 and prostaglandin(s) in lipopolysaccharide-induced bone resorption in vivo. Infect Immun 70:3915-3922. (Pubitemid 34666032)
16. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, Kawagoe J, Takahashi K, Yada-Hashimoto N, Seino-Noda H, Sakata M, Motoyama T, Kurachi H, Testa JR, Tasaka K, Murata Y. 2004. Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin Cancer Res 10:7645-7654. (Pubitemid 39557528)
17. Nakamura H, Hirata A, Tsuji T, Yamamoto T. 2003. Role of osteoclast extracellular signal-regulated kinase (ERK) in cell survival and maintenance of cell polarity. J Bone Miner Res 18:1198-1205. (Pubitemid 37294912)
18. Pavlos NJ, Xu J, Riedel D, Yeoh JS, Teitelbaum SL, Papadimitriou JM, Jahn R, Ross FP, Zheng MH. 2005. Rab3D regulates a novel vesicular trafficking pathway that is required for osteoclastic bone resorption. Mol Cell Biol 25:5253-5269. (Pubitemid 40781122)
19. Perera PY, Qureshi N, Vogel SN. 1996. Paclitaxel (Taxol)-induced NF-kappaB translocation in murine macrophages. Infect Immun 64:878-884. (Pubitemid 26065562)
20. Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Mangioni C, Simonsen E, James K, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R, Swenerton K, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lidvall B, Bacon M, Birt A, Andersen J, Zee B, Paul J, Pecorelli S, Baron B, McGuire W. 2003. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer 13(Suppl 2): 144-148. (Pubitemid 38228756)
21. Ray S, Ponnathpur V, Huang Y, Tang C, Mahoney ME, Ibrado AM, Bullock G, Bhalla K. 1994. 1-beta-D-arabinofuranosylcytosine-, mitoxantrone-, and paclitaxel-induced apoptosis in HL-60cells: Improved method for detection of internucleosomal DNA fragmentation. Cancer Chemother Pharmacol 34:365-371.
22. Scaife RM. 2005. Selective and irreversible cell cycle inhibition by diphenyleneiodonium. Mol Cancer Ther 4:876-884. (Pubitemid 40909070)
23. Stone AA, Chambers TC. 2000. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp Cell Res 254:110-119. (Pubitemid 30066737)
24. Teitelbaum SL. 2007. Osteoclasts: What do they do and how do they do it? Am J Pathol 170:427-435. (Pubitemid 47339379)
25. Wall ME, Wani MC. 1996. Camptothecin and taxol: From discovery to clinic. J Ethnopharmacol 51:239-253 discussion 253-4.
26. Wang C, Steer JH, Joyce DA, Yip KH, Zheng MH, Xu J. 2003. 12-Otetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation. J Bone Miner Res 18: 2159-2168. (Pubitemid 37463309)
27. Xing L, Bushnell TP, Carlson L, Tai Z, Tondravi M, Siebenlist U, Young F, Boyce BF. 2002. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANKand cytokine-mediated osteoclastogenesis. J Bone Miner Res 17:1200-1210. (Pubitemid 34680496)
28. Xu J, Feng HT, Wang C, Yip KH, Pavlos N, Papadimitriou JM, Wood D, Zheng MH. 2003. Effects of Bafilomycin A1: An inhibitor of vacuolar H (+)-ATPases on endocytosis and apoptosis in RAW cells andRAW cell-derived osteoclasts. J Cell Biochem 88:1256-1264. (Pubitemid 36397463)
29. Xu J, Tan JW, Huang L, Gao XH, Laird R, Liu D, Wysocki S, Zheng MH. 2000. Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-kappaB ligand. J Bone Miner Res 15:2178-2186.
30. Xu J, Wu HF, Ang ES, Yip K, Woloszyn M, Zheng MH, Tan RX. 2009. NFkappaB modulators in osteolytic bone diseases. Cytokine Growth Factor Rev 20:7-17.
31. Yip KH, Feng H, Pavlos NJ, Zheng MH, Xu J. 2006. p62 ubiquitin bindingassociated domain mediated the receptor activator of nuclear factor-kappaB ligand-induced osteoclast formation: A new insight into the pathogenesis of Paget's disease of bone. Am J Pathol 169:503-514. (Pubitemid 44156310)
32. Yip KH, Zheng MH, Feng HT, Steer JH, Joyce DA, Xu J. 2004. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity. J Bone Miner Res 19:1905-1916. (Pubitemid 41103442)
33. Yip KH, Zheng MH, Steer JH, Giardina TM, Han R, Lo SZ, Bakker AJ, Cassady AI, Joyce DA, Xu J. 2005. Thapsigargin modulates osteoclastogenesis through the regulation of RANKL-induced signaling pathways and reactive oxygen species production. J Bone Miner Res 20:1462-1471. (Pubitemid 41033530)